1v1 Institutional Counterparty Comparison
Chainapsis vs InBioGen: Regulation, 6D Ratings & Safety Audit
Deterministic head-to-head benchmarking of Chainapsis (Chainapsis) and InBioGen (InBioGen Co Ltd) across primary regulatory filings, statutory Tier-1 authorisations, 6-Dimension compliance scores, execution software, and warning exposure.
Coverage: Selected financial institution records: Singapore, Asia-Pacific, the Middle East and emerging markets
Chainapsis and InBioGen are statistically tied in composite 6D scoring (5.0 vs 5.0)
On supervisory breadth, Chainapsis holds 0 active regulated licence(s) (0 Tier-1) out of 0 total filings and 0 warning count(s), whereas InBioGen holds 0 active regulated licence(s) (0 Tier-1) out of 0 total filings and 0 warning count(s). Allocators should inspect the individual licence numbers and contracting legal entities below before onboarding.
6-Dimension Quantitative Scorecard Comparison
Head-to-head breakdown across all 6 proprietary evaluation dimensions (0.0–10.0 scale).
| Evaluation Dimension | Methodology Weight | Chainapsis | InBioGen | Score Delta | Dimension Leader |
|---|---|---|---|---|---|
| Overall Composite 6D Score | 100% Composite | 5.0 | 5.0 | 0.0 | Statistical Tie |
| Regulatory & Licensing Integrity (riskScore) | 30% Weight | 1.0 | 5.0 | +4.0 | InBioGen |
| Execution & Software Infrastructure (industryScore) | 20% Weight | 1.0 | 3.0 | +2.0 | InBioGen |
| User Reputation & Complaint Telemetry (userScore) | 20% Weight | 0.0 | 0.0 | 0.0 | Statistical Tie |
| Institutional Brand Longevity (brandScore) | 15% Weight | 1.0 | 5.0 | +4.0 | InBioGen |
| Global Market Influence & Footprint (influenceScore) | 15% Weight | 1.0 | 5.0 | +4.0 | InBioGen |
Visual Architecture Benchmark: Chainapsis vs InBioGen
Vector comparison exhibit generated from live supervisory snapshot metrics.
Regulatory Standing, Entity & Platform Comparison
Structural comparison of supervisory authorisations, domicile, execution terminals, and risk telemetry.
| Audit Attribute | Chainapsis | InBioGen |
|---|---|---|
| Primary Legal Name | Chainapsis | InBioGen Co Ltd |
| Source Risk Classification | Risk level not supplied | Risk level not supplied |
| Active Regulated / Total Filings | 0 regulated / 0 total (0 Tier-1) | 0 regulated / 0 total (0 Tier-1) |
| Recorded Certificate Numbers | None on file | None on file |
| Registered Domicile / Address | KR | 14F, 61, Digital-ro 26-gil, Guro-gu, Seoul, Republic of Korea |
| Offered Asset Classes & Services | Multi-asset financial services | Multi-asset financial services |
| Execution Software & Terminals | Proprietary / Web Platform | Proprietary / Web Platform |
| Supported Client Languages | English | English |
| Warning / Exposure Count | 0 recorded warning(s) | 0 recorded warning(s) |
| Specialized Sub-Page Audits |
Related 1v1 Institutional Comparisons
Compare Chainapsis and InBioGen against other regulated peers in our selected financial institution records: singapore, asia-pacific, the middle east and emerging markets slice.
Frequently Asked Questions: Chainapsis vs InBioGen
Deterministic counterparty comparison answers derived from supervisory records.
Which institution has stronger regulatory oversight: Chainapsis or InBioGen?
Both Chainapsis and InBioGen hold 0 regulated licence record(s) in our dataset. Specifically, Chainapsis maintains 0 total recorded filing(s) (none on file) with 0 warning flag(s), whereas InBioGen maintains 0 recorded filing(s) (none on file) with 0 warning flag(s). Always confirm the specific subsidiary onboarding your account on the official regulator register.
How do the 6D quantitative compliance scores compare between Chainapsis and InBioGen?
In World Firm Ledger's 6-Dimension scoring matrix (0.0–10.0 scale), Chainapsis records an Overall Score of 5.0 (Risk & Licensing: 1.0, Brand: 1.0, Market Influence: 1.0, User Reputation: 0.0, Execution & Software: 1.0), compared with InBioGen at 5.0 Overall (Risk & Licensing: 5.0, Brand: 5.0, Market Influence: 5.0, User Reputation: 0.0, Execution & Software: 3.0).
How do Chainapsis and InBioGen differ in trading platforms and asset classes?
Chainapsis lists general financial services with execution software [proprietary/web execution], while InBioGen lists general financial services with execution software [proprietary/web execution]. Counterparties should verify FIX/API connectivity, server routing topology, and negative balance protection per entity.
Which counterparty carries lower regulatory warning and complaint exposure: Chainapsis or InBioGen?
Chainapsis carries a "Risk level not supplied" classification with 0 warning/exposure count(s) and 0 user comment(s), while InBioGen carries a "Risk level not supplied" classification with 0 warning/exposure count(s) and 0 user comment(s).
Structured against supervisory register snapshots and public regulatory filings. Verify your contracting legal entity and current authorisation status directly on the issuing regulator’s official register before transacting.